πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Eloxx Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELI-002

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.

Tags: Biotechnology, Cancer Treatment, Clinical-stage, Immunotherapy, Vaccines

Symbol: ELTX

Recent Price: $5.00

Industry: Biotechnology

CEO: Mr. Robert T. Connelly

Sector: Healthcare

Employees: 32

Address: 451 D Street, Boston, MA 02210

Phone: 857-209-0050

Last updated: 2024-12-31

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

losmapimod and FTX-6058

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States.

Tags: FTX-6058, biopharmaceutical, clinical-stage, facioscapulohumeral muscular dystrophy, genetically defined diseases, hemoglobinopathies, losmapimod, sickle cell disease

Symbol: FULC

Recent Price: $4.68

Industry: Biotechnology

CEO: Mr. Alexander C. Sapir

Sector: Healthcare

Employees: 76

Address: 26 Landsdowne Street, Cambridge, MA 02139

Phone: 617 651 8851

Last updated: 2024-12-31

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ZYESAMI, NRX-100, NRX-101

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

Tags: CNS disorders, COVID-19 treatment, bipolar depression, clinical-stage pharmaceutical, pulmonary diseases, suicidal behavior

Symbol: NRXP

Recent Price: $1.53

Industry: Biotechnology

CEO: Dr. Jonathan C. Javitt M.D., M.P.H.

Sector: Healthcare

Employees: 2

Address: 1201 Orange Street, Wilmington, DE 19801

Phone: 484 254 6134

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten BΓΆnnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Medium

AMX0035

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their leading product, AMX0035, is aimed at ALS treatment.

Tags: ALS, AMX0035, biopharmaceutical, neurodegenerative diseases, therapeutics

Symbol: AMLX

Recent Price: $3.84

Industry: Biotechnology

CEO: Mr. Joshua B. Cohen

Sector: Healthcare

Employees: 384

Address: 43 Thorndike Street, Cambridge, MA 02141

Phone: 617 682 0917

Leadership

  • Linda A. Arsenault, Chief Human Resources Officer
  • Camille L. Bedrosian, MD, Chief Medical Officer
  • Josh Cohen, Co-CEO & Co-Founder
  • James M. Frates, Chief Financial Officer
  • Tom Holmes, Chief Technical Operations Officer
  • Justin Klee, Co-CEO & Co-Founder
  • Gina M. Mazzariello, Chief Legal Officer & General Counsel
  • Rudolph Tanzi, PhD, Founding Chair of the Amylyx SAB
  • Wally Gilbert, Special Advisor
  • Kari Firestone, Director
  • Paul Fonteyne, Director
  • George Milne, Chairman
  • Daphne Quimi, Director
  • Bernhardt G. Zeiher, MD, FACP, FCCP, Director

Last updated: 2024-12-31

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. logo
Market Cap: High
Employees: Low

therapeutic monoclonal and bispecific antibodies

Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.

Tags: biopharmaceutical, bispecific antibodies, cancer treatment, inflammatory diseases, monoclonal antibodies

Symbol: CLDX

Recent Price: $25.12

Industry: Biotechnology

CEO: Mr. Anthony S. Marucci M.B.A.

Sector: Healthcare

Employees: 160

Address: Perryville III Building, Hampton, NJ 08827

Phone: 908 200 7500

Leadership

  • Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
  • Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
  • Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
  • Sam Martin, Senior Vice President and Chief Financial Officer
  • Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
  • Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
  • Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
  • Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
  • Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
  • Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
  • Keith L. Brownlie, Former Partner, Ernst & Young LLP
  • Herbert J. Conrad, Former President, Roche Pharmaceuticals US
  • James J. Marino, J.D., Former Partner, Dechert LLP
  • Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
  • Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
  • Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
  • Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
  • Carl June, M.D.,
  • Michel Nussenzweig, M.D., Ph.D.,
  • Marc E. Rothenberg M.D., Ph.D.,
  • Joseph Schlessinger, Ph.D.,
  • Louis Weiner, M.D.,

Last updated: 2024-12-31

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELX-02

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.

Tags: ELX-02, biopharmaceutical, clinical trials, cystic fibrosis, nephropathic cystinosis, rare diseases, ribosome modulation

Symbol: ELOX

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Sumit Aggarwal M.B.A.

Sector: Healthcare

Employees: 18

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 781 577 5300

Last updated: 2024-12-31

FibroGen, Inc.

FibroGen, Inc. logo
Market Cap: Lowest
Employees: Medium

Roxadustat, Pamrevlumab

Fibro Gen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics to treat serious unmet medical needs, including treatments for anemia, idiopathic pulmonary fibrosis, and Duchenne muscular dystrophy.

Tags: anemia, antibody, biopharmaceutical, cancer, kidney disease, pulmonary fibrosis, therapeutics

Symbol: FGEN

Recent Price: $0.53

Industry: Biotechnology

CEO: Mr. Thane Wettig

Sector: Healthcare

Employees: 486

Address: 409 Illinois Street, San Francisco, CA 94158

Phone: 415 978 1200

Last updated: 2024-12-31

Inozyme Pharma, Inc.

Inozyme Pharma, Inc. logo
Market Cap: Medium
Employees: Lowest

INZ-701

Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.

Tags: ABCC6, ENPP1, INZ-701, biopharmaceutical, calciphylaxis, genetic diseases, mineralization, rare diseases, therapeutics

Symbol: INZY

Recent Price: $2.82

Industry: Biotechnology

CEO: Dr. Douglas A. Treco Ph.D.

Sector: Healthcare

Employees: 59

Address: 321 Summer Street, Boston, MA 02210

Phone: 857 330 4340

Leadership

  • Doug Treco, Ph.D., CEO, Chairman of Board of Directors
  • Gayle Gironda, Senior Vice President and Chief People Officer
  • Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
  • Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
  • Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
  • Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
  • Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
  • Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
  • David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
  • Sarah Bhagat, Ph.D., Director
  • Reinaldo M. Diaz, MBA, Director
  • Martin Edwards M.D., MBA, Director
  • Erik Harris, MBA, Director
  • Rob Hopfner, Rph, Ph.D., MBA, Director
  • Edward Mathers, Director
  • Lynne Sullivan, MST, Director

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Low

LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004

Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.

Tags: APOE4, Batten disease, acquired diseases, cardiomyopathy, gene therapy, genetic medicine, hereditary diseases

Symbol: LXEO

Recent Price: $6.54

Industry: Biotechnology

CEO: Mr. R. Nolan Townsend

Sector: Healthcare

Employees: 69

Address: 345 Park Avenue South, New York, null 10010

Phone: 212-547-9879

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd. logo
Market Cap: Lowest
Employees: Lowest

QRX003

Quoin Pharmaceuticals, Ltd. is a specialty pharmaceutical company focused on developing therapeutic products for rare and orphan diseases, including QRX003 for Netherton Syndrome.

Tags: Netherton Syndrome, QRX003, QRX004, QRX006, orphan diseases, pharmaceuticals, rare diseases, therapeutics

Symbol: QNRX

Recent Price: $0.70

Industry: Biotechnology

CEO: Dr. Michael Myers Ph.D.

Sector: Healthcare

Employees: 4

Address: 42127 Pleasant Forest Court, Ashburn, VA 20148-7349

Phone: 703 980 4182

Last updated: 2024-12-31

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. logo
Market Cap: High
Employees: Medium

Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.

Tags: Crysvita, Dojolvi, Evkeeza, Mepsevii, biopharmaceutical, gene therapy, genetic diseases, rare diseases

Symbol: RARE

Recent Price: $42.27

Industry: Biotechnology

CEO: Dr. Emil D. Kakkis M.D., Ph.D.

Sector: Healthcare

Employees: 1276

Address: 60 Leveroni Court, Novato, CA 94949

Phone: 415 483 8800

Last updated: 2024-12-31

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Gene Therapies

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.

Tags: Biotechnology, Clinical Stage, Gene Therapy, Healthcare, Rare Diseases

Symbol: RCKT

Recent Price: $12.03

Industry: Biotechnology

CEO: Dr. Gaurav D. Shah M.D.

Sector: Healthcare

Employees: 268

Address: 9 Cedarbrook Drive, Cranbury, NJ 08512

Phone: 609 659 8001

Last updated: 2024-12-31

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

mavorixafor

X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases, with its lead product mavorixafor in advanced clinical trials.

Tags: CXCR4, biopharmaceutical, clinical trials, mavorixafor, rare diseases, therapeutics

Symbol: XFOR

Recent Price: $0.81

Industry: Biotechnology

CEO: Dr. Paula Ragan Ph.D.

Sector: Healthcare

Employees: 127

Address: 61 North Beacon Street, Boston, MA 02134

Phone: 857 529 8300

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Exelixis, Inc.

Exelixis, Inc. logo
Market Cap: Highest
Employees: Medium

CABOMETYX, COMETRIQ, COTELLIC, MINNEBRO

Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines to treat cancers, primarily in the United States. Its products include CABOMETYX, COMETRIQ, COTELLIC, and MINNEBRO.

Tags: biotechnology, cancer treatment, oncology, pharmaceuticals

Symbol: EXEL

Recent Price: $33.70

Industry: Biotechnology

CEO: Dr. Michael M. Morrissey Ph.D.

Sector: Healthcare

Employees: 1310

Address: 1851 Harbor Bay Parkway, Alameda, CA 94502

Phone: 650 837 7000

Last updated: 2024-12-31

Immix Biopharma, Inc.

Immix Biopharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

IMX-110, IMX-111, IMX-120

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.

Tags: Biopharmaceuticals, Clinical Trials, Inflammation, Oncology, Tissue-Specific Therapeutics

Symbol: IMMX

Recent Price: $2.36

Industry: Biotechnology

CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.

Sector: Healthcare

Employees: 14

Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064

Phone: 310 651 8041

Last updated: 2024-12-31